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Abstract
Background: The purpose of this study is to validate a new five-tiered prognostic classification system to better
discriminate cancer-specific mortality in men diagnosed with primary non-metastatic prostate cancer.
Methods: We applied a recently described five-strata model, the Cambridge Prognostic Groups (CPGs 1-5), in
two international cohorts and tested prognostic performance against the current standard three-strata
classification of low-, intermediate- or high-risk disease. Diagnostic clinico-pathological data for men obtained
from the Prostate Cancer data Base Sweden (PCBaSe) and the Singapore Health Study were used. The main
outcome measure was prostate cancer mortality (PCM) stratified by age group and treatment modality.
Results: The PCBaSe cohort included 72,337 men, of whom 7162 died of prostate cancer. The CPG model
successfully classified men with different risks of PCM with competing risk regression confirming significant
intergroup distinction (p < 0.0001). The CPGs were significantly better at stratified prediction of PCM compared to the
current three-tiered system (concordance index (C-index) 0.81 vs. 0.77, p < 0.0001). This superiority was maintained for
every age group division (p < 0.0001). Also in the ethnically different Singapore cohort of 2550 men with 142 prostate
cancer deaths, the CPG model outperformed the three strata categories (C-index 0.79 vs. 0.76, p < 0.0001). The model
also retained superior prognostic discrimination in the treatment sub-groups: radical prostatectomy (n = 20,586),
C-index 0.77 vs. 074; radiotherapy (n = 11,872), C-index 0.73 vs. 0.69; and conservative management (n = 14,950),
C-index 0.74 vs. 0.73. The CPG groups that sub-divided the old intermediate-risk (CPG2 vs. CPG3) and high-risk
categories (CPG4 vs. CPG5) significantly discriminated PCM outcomes after radical therapy or conservative
management (p < 0.0001).
Conclusions: This validation study of nearly 75,000 men confirms that the CPG five-tiered prognostic model
has superior discrimination compared to the three-tiered model in predicting prostate cancer death across
different age and treatment groups. Crucially, it identifies distinct sub-groups of men within the old intermediate-risk
and high-risk criteria who have very different prognostic outcomes. We therefore propose adoption of the CPG model
as a simple-to-use but more accurate prognostic stratification tool to help guide management for men with newly
diagnosed prostate cancer.
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Background
Prostate cancer is a growing burden on health care
systems worldwide [1, 2]. With rising disease awareness,
an increasing proportion of men are presenting with non-
metastatic disease [3, 4]. There is an urgent need to
improve the prognostic precision for men with non-
metastatic disease since management options are becom-
ing more diversified, e.g. the increasing use of active
surveillance for low-risk disease, and, conversely, due to
the recognition that more intensive, combined treatment
is needed in high-risk disease [5, 6]. Current risk stratifica-
tion models were primarily developed to predict therapy
failure and not the risk of prostate cancer death. More-
over, they are almost exclusively based on surgically and
radiotherapy-treated men and do not include men who
are managed conservatively [7, 8]. Nevertheless, the sim-
ple clinico-pathological variables that go into these models
make them easy to use, and they are commonly the first
triaging step recommended by many national and inter-
national guidelines for clinical decision-making [9–12].
To address this, we recently remodelled the compo-
nents (histological grade, clinical stage and prostate-
specific antigen (PSA) at diagnosis) that comprise the
currently used risk classification systems [13]. In a new
five-strata model, we also incorporated the new histo-
logical grade grouping recently recommended by the
International Society of Urological Pathology (ISUP),
which has been shown to be a better predictor of disease
recurrence and progression than the Gleason sum alone
[14, 15]. In a cohort of nearly 12,000 UK men, we found
that the new model stratified the risk of prostate cancer
death significantly better than the widely adopted three-
tiered classification of low, intermediate and high risk
[10–13]. In this paper, we report validation of this
model, called the Cambridge Prognostic Groups (CPGs),
in two separate, ethnically different cohorts: 72,337
Swedish men and 2550 men from a Southeast Asian
population. Using the Swedish study group, we also
assessed the utility of the CPG model in pre-treatment
prognosis in men who had surgery, radiotherapy or
conservative management.
Methods
Study cohorts
Prostate Cancer data Base Sweden
The Prostate Cancer data Base Sweden (PCBaSe) 3.0
was created through record linkages between the Na-
tional Prostate Cancer Register (NPCR) of Sweden and
several other population-based, nationwide health care
registers and demographic databases [16]. The capture
rate of the NPCR is 98% compared to that of the
Swedish Cancer Registry, to which registration is man-
dated by law [17]. Information on the underlying and
contributing causes and on the date of death was
obtained from the Cause of Death Register, which
captures all deaths in Sweden. The overall agreement be-
tween the Cause of Death Register and reviewed medical
records is approximately 86% (95% confidence interval
85–87%) [18]. PCBaSe does not include information on
sub-categories for local clinical stages T2 and T3. We
obtained data of 80,803 men in PCBaSe, accrued from
2000 to 2010, with no evidence of metastatic disease
(Mx or M0) and PSA < 100 ng/ml. All men were
followed until death, emigration or to 31 December
2015, whichever occurred first. The outcome event for
each man was one of the following: alive, prostate
cancer-specific death or other causes of death. To assess
prognostic performance, each man was assigned to the
appropriate CPG using diagnostic clinical parameters
including PSA at diagnosis (nanograms per millilitre),
clinical T stage and Gleason Grade Group as previously
described [13] (Table 1). Because these criteria were
essential to assigning a CPG category, 8466 men had to
be excluded because of a lack of data in one or more of
these fields. As a comparator we also assigned each
individual to the appropriate group in the widely
adopted three-strata model (low, intermediate or high
risk) published in many national and international
guidelines including the UK [10–12]. For this paper we
have used the UK National Institute for Health and Care
Excellence (NICE) version as the reference, which is
itself based on the D’Amico criteria first published in
1997 [7, 10]. For treatment-specific analysis we focused
on men managed by primary radical prostatectomy,
radical radiotherapy or conservative management. We
did not have available data on any subsequent treat-
ments men may have received or the use of concurrent
Table 1 Criteria of the new Cambridge Prognostic Groups for
non-metastatic prostate cancer
Cambridge Prognostic
Group (CPG)
Criteria
1 Gleason score 6 (Grade Group 1) AND PSA < 10
ng/ml AND Stages T1–T2
2 Gleason score 3 + 4 = 7 (Grade Group 2)
OR PSA 10–20 ng/ml AND Stages T1–T2
3 Gleason score 3 + 4 = 7 (Grade Group 2)
AND PSA 10–20 ng/ml AND Stages T1–T2
OR
Gleason 4 + 3 = 7 (Grade Group 3) AND
Stages T1–T2
4 One of Gleason score 8 (Grade Group 4)
OR PSA > 20 ng/ml OR Stage T3
5 Any combination of Gleason score 8
(Grade Group 4), PSA > 20 ng/ml or
Stage T3
OR
Gleason score 9–10 (Grade Group 5)
OR
Stage T4
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adjuvant treatments. In the PCBaSe cohort, the term
conservative management was until 2008 used to denote
both active surveillance and watchful waiting. For sim-
plicity, we have therefore also used the term conserva-
tive management for treatments that from 2008 were
categorised as either active surveillance or watchful wait-
ing. Any individuals with missing data fields were
excluded from the analysis, as all components were
crucial to assigning a prognostic group. Median follow-
up was 7 years, and 51% of the cohort had follow-up for
10 years or until death. Ethical permission for data
collection for PCBaSe was provided by the Research Eth-
ics Board at Umeå University.
Singapore General Hospital prostate cancer database
The Singapore Health Study identified incident prostate
cancer cases and deaths amongst cohort members by
record linkage of the cohort database with the population-
based Singapore Cancer Registry and the Singapore
Registry of Births and Deaths. Dedicated cancer registrars
prospectively collected and maintained data on all prostate
cancers diagnosed and/or treated at Singapore General
Hospital. Ethics for data collection and use is covered by
CIRB ref. 2009/1053/D approved by the Singhealth
Centralised Institutional Review Board. As in the PCBaSe
cohort, only men with no evidence of metastatic disease
and PSA < 100 ng/ml were included and stratified by the
CPG or three-strata model (final cohort size of 2550).
Median follow-up was shorter at 4.1 years, and 21.1% of
the cohort had follow-up for 10 years or until death. As
before, each patient’s case outcome was recorded as alive
or prostate cancer-specific death or other causes of death.
All data was anonymised at the source at both inter-
national centres before being used for analysis.
Statistical analysis
The statistical methodology closely followed our first
publication on the model, and the setting, eligibility cri-
teria, outcome and predictors were similar to those of
our development cohort [13]. The primary outcome of
interest was the risk of prostate cancer mortality (PCM).
All-cause mortality was also recorded. To study survival
differences between prognostic groups, we applied a Cox
proportional hazards regression model and the log rank
test with pair-wise comparisons. “Low risk” was the ref-
erence group in the NICE model and “CPG1” in the
CPGroup model. The null hypothesis was no difference
between groups in the probability of prostate cancer
death. For visual comparison and to explore estimation
of survival time, cumulative incidence curves were con-
structed. Competing hazards risk regression using the
Fine-Gray test was applied to include the influence of
non-cancer deaths on model performance. For model dis-
crimination, we used the somersd package to compute the
rank parameters concordance index. Sub-hazard ratios
were used in computation instead of hazard ratio to
account for competing risks from other causes of death
[19]. We then compared the performance of the new
model to the three-tiered NICE groups. In the PCBaSe co-
hort, we further explored prognostic performance by
stratifying patients according to three age groups (< 60,
60–69 and ≥ 70 years old). We also investigated the CPG
model’s prognostic performance by treatment types, fo-
cusing on radical prostatectomy, radical radiotherapy and
conservative management. For each modality, we com-
puted hazard ratios and concordance index (C-index) as
before with inclusion of competing risks of death similarly
as in the initial study [13]. Statistical analyses were per-
formed using Stata Statistical Software, Release 14 (Stata-
Corp LP, 2015, College Station, TX, USA).
Results
Prognostic performance in the PCBaSe cohort
The final PCBaSe cohort included 72,337 men, of whom
7162 died of prostate cancer. A further 15,921 men died
of other causes during follow-up. Forty-five percent
received radical treatment, either by radical prostatec-
tomy (n = 20,586) or radical radiotherapy (n = 11,872)
while 14,950 (21%) were managed conservatively. The
remainder had other treatments or had missing records
(Additional file 1: Table S1). Additional file 2: Table S2
shows the distribution of the Swedish cohort by age and
diagnostic clinico-pathological variables. In this cohort,
the CPG model classified men into the five sub-groups
with very different risks of PCM in a competing risk
analysis (p < 0.0001 for all groups) (Table 2). Pair-wise
competing risk regression also confirmed significant
intergroup discrimination (p < 0.0001 for all comparisons)
(Table 3). Visual assessment of model discrimination is fur-
ther shown by the cumulative incidence curves in Fig. 1a
demonstrating clear differences in outcomes between the
groups. The corresponding curves for the standard three-
strata model are shown in Fig. 1b. These results reproduce
our initial findings and confirm the utility of the CPG sub-
groups as a valuable prognostic tool at the time of prostate
cancer diagnosis [13]. The cumulative comparative 10-year
mortality rates from prostate cancer and other causes of
death are shown for each CPG category in Fig. 2. We tested
how the overall prognostic performance of the CPG model
compared to the NICE categories. In the PCBaSe cohort,
the NICE groups demonstrated a C-index from competing
risk analysis of 0.77 for predicting PCM. The CPG model,
however, had a significantly superior C-index of 0.81
(p < 0.001) (Table 4). Finally, we tested if model per-
formance was influenced by patient age. In this analysis
the CPG model again outperformed the NICE model in
every age group tested (Additional file 3: Table S3).
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Prognostic performance in a Singapore cohort
We next sourced a separate cohort of 2550 men from
Singapore of very different ethnicity (Chinese n = 2137,
Indian n = 136, Malay n = 143, others n = 134). In this
cohort there were 142 prostate cancer deaths and 266
deaths from other causes. Men were predominantly treated
by radical therapy (72%): radical prostatectomy (n = 1012),
radical radiotherapy (n = 824). Another 539 (21%) were
managed conservatively. Additional file 4: Table S4 shows
the distribution by clinical pathological variables. In this
cohort, the CPG model continued to show progressively
higher hazard ratios except between CPG1 and CPG2,
where there were only 12 prostate cancer deaths
(Additional file 5: Table S5). Overall, the model prognostic
performance from competing risk analysis was again
significantly superior to that of the three-strata system, with
a C-index of 0.79 vs. 0.76 (p < 0.001) (Table 4).
Clinical utility of the CPG model in treatment-specific
prognosis
Sub-analysis of the CPG performance across different
treatment settings was performed in the PCBaSe cohort.
Amongst the radical therapy groups, sub-dividing
traditional intermediate-risk disease into CPG2 and
CPG3 identified men with very different PCM outcomes
(p < 0.0001, Additional file 6: Table S6 and Additional
file 7: Table S7). Notably, CPG3 (two intermediate-risk
factors or histological Grade Group 3 alone) conferred a
much poorer outcome compared to CPG2 regardless of
whether men had surgery or radiotherapy (Additional
file 8: Table S8). Indeed, pair-wise competing risk regres-
sion showed that CPG3 PCM outcomes were generally
very similar to that of CPG4 (men with a single high-
risk factor). In both radical treatment groups, however,
men in CPG5 had the worst outcomes. Even compared
to CPG4 alone these men had a nearly threefold higher
risk of PCM (Additional file 6: Table S6, Additional file
7: Table S7 and Additional file 8: Table S8). Amongst
men who had conservative management, only 3% of
men in CPG1 died of prostate cancer, reinforcing the
overwhelming indolent behaviour of cancers in this sub-
group. For intermediate-risk disease it was particularly
notable that men with CPG3 had a more than twofold
higher risk of prostate cancer death compared to men in
CPG2. The number of men who had conservative
management in CPGs 3–5 was, however, low (represent-
ing only 20% of this sub-cohort); hence, more detailed
interpretation of these groups was deemed unreliable.
Overall, the CPG model again consistently outperformed
the current three-strata risk groups in terms of prognos-
tic performance regardless of treatment type (Table 5).
Additional file 9: Table S9 shows the comparative
cancer-related mortality between the three treatment
options categorised by CPG sub-groups. Additional file
10: Table S10 shows the cross tabulation of distribution
between the three-strata model and the CPG criteria.
Discussion
The CPG model, now tested in three different inter-
national cohorts in two studies including 86,732 primary
prostate cancers, delivers distinct cancer mortality sub-
groups with a high prognostic accuracy. The prognostic
power of the model was very consistent between our de-
velopment cohort and this validation study [13]. To our
knowledge, the CPG model is the first risk stratification
tool to have been derived from and validated in cohorts
of newly diagnosed men using cancer death as the pri-
mary outcome. Our tested cohorts also included signifi-
cant proportions of locally advanced cases (12 and 16%)
and men managed conservatively (19 and 21%), which
reflect most real-world practices where PSA screening is
uncommon and unlikely to be implemented [5, 20–22].
The intermediate-risk group is the largest category of
patients in contemporary cohorts [5]. The CPG model
divides this group into two categories: CPG2, which is
associated with a relatively good prognosis, and CPG3 (a
combination of intermediate-risk factors or Gleason
Table 2 Distribution of cases/deaths and sub-hazard ratios from competing risk analysis for each Cambridge Prognostic Group
(CPG) category in the PCBaSe cohort (n = 72,337)
CPG Number of men Deaths from prostate cancer Deaths from other causes Sub-hazard ratio (95% confidence interval) p value
1 25,303 482 3740 Reference NA
2 14,796 628 2912 2.30 (2.04–2.59) < 0.0001
3 7354 589 1532 4.70 (4.17–5.30) < 0.0001
4 13,506 1831 4011 7.42 (6.71–8.19) < 0.0001
5 11,378 3632 3726 20.52 (18.66–22.55) < 0.0001
Total 72,337 7162 15,921 _ _
Table 3 Competing risk regression analysis of Cambridge
Prognostic Groups (CPGs) in the PCBaSe cohort
CPG comparison Sub-hazard ratio 95% confidence interval p value
2 vs. 1 2.30 2.04–2.59 < 0.0001
3 vs. 2 2.11 1.89–2.36 < 0.0001
4 vs. 3 1.56 1.42–1.72 < 0.0001
5 vs. 4 2.72 2.58–2.88 < 0.0001
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Grade Group 3 on its own), with a substantially higher
mortality risk despite radical therapy. This data supports
the recent work of Raldow et al., where men with
multiple intermediate-risk features had higher rates of
prostate cancer death following brachytherapy [23]. Our
results further suggest that many men with CPG2
disease may potentially be candidates for conservative
management, at least initially, and thus avoid the mor-
bidity of unnecessary treatment. In contrast, men with
CPG3 should not be managed conservatively, as they
have a much higher baseline risk of PCM. We do inter-
pret this with caution, as our data may be potentially
biased by treatment selection. Nevertheless, our results
are supported by the work of Musunura et al., who
observed a similar worse survival outcome from active
surveillance in men with a combination of Gleason 7
and a high PSA [24]. Our distinction between CPG2 and
CPG3 has now also been independently identified by the
new 2017 American Urological Association (AUA)/
American Society for Radiation Oncology (ASTRO)/So-
ciety of Urologic Oncology (SUO) localised prostate
cancer guidelines. They have defined a favourable and
unfavourable category amongst intermediate-risk can-
cers, the criteria of which perfectly match the ones used
here in the CPG2 and CPG3 categories [25]. Although
the AUA/ASTRO/SUO definitions were not derived
a
b
Fig. 1 Cumulative incidence curves for prostate cancer-specific survival in the PCBaSe cohort (n = 72,337) stratified by the a Cambridge Prognostic Groups
and b current three-strata risk groups as a comparator model
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from primary research, they endorse our evidence-based
distinction from a large cohort study that these sub-
groups are linked to very different mortality outcomes.
Consistently across all treatments, the split of the
traditional high-risk category into CPG4 and CPG5 (mul-
tiple high-risk features) defined groups with very different
risks of cancer death. CPG5 men had more than double
the risk of PCM, even when compared to CPG4. These re-
sults support the findings of previous studies reporting
that multiple high-risk factors confer a much worse
treatment-specific outcome [26, 27]. Our study is, how-
ever, the first to show this effect in a very large cohort and
simultaneously across different treatment types. Men with
CPG3 and CPG4 disease represented statistically different
Fig. 2 Ten-year prostate cancer and other-cause mortality rates stratified by each Cambridge Prognostic Group (CPG) category in the PCBaSe
cohort (n = 72,337). Red prostate cancer mortality, blue other-cause mortality
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prognostic sub-groups in our overall cohort analysis with
distinctly different outcomes in intergroup comparisons.
This mirrors the findings of our initial development study
[13]. However, we do show for the first time that they may
have very similar outcomes when treated by radical ther-
apy. The reason for this may be that these treatment sub-
cohorts were too small to pick up a difference, but our
findings do support the notion that CPG3 likely represents
a distinct aggressive sub-type of intermediate-risk disease
more akin to the traditional high-risk disease designation.
A consistent criticism of risk and prognostic groupings
is that they do not address intra-group heterogeneity
[28]. As an example, Joniau et al. showed that amongst
very high-risk men (in our study, CPG5) having surgery,
the sub-group T3 and PSA > 20 had better outcomes
compared to men with very high Gleason score 9–10
disease [27]. Although this criticism could also be
applied to the CPG, we believe that our stratification
system is an important first step in providing a more ac-
curate but still simple framework for more individualised
decision-making in non-metastatic prostate cancer.
Hence, when we looked at our very high-risk group, the
different categories did all have significantly worse mor-
tality outcomes compared to CPG4 (the next prognostic
level), p < 0.001 in all comparisons. In terms of practical
usage, we believe that the CPG groups add significant
clinical benefit. For example, men in CPG1 should be
preferentially steered towards active surveillance. Many
men in CPG2 are also likely to do well from this option
but may need a more intensive surveillance schedule. In
contrast, men in CPG3 and CPG4 clearly need curative
therapy, and for these men the added use of individua-
lised estimates of treatment outcomes could be very
helpful. Bespoke biomarkers could also be used which
are more appropriate for the disease context. A recent
example is the work of Ahmad et al., who showed that
adding a DNA methylation index to the Cancer of the
Prostate Risk Assessment (CAPRA) score improved pre-
diction of PCM in men with intermediate-risk disease
(area under the curve (AUC) from 0.62 to 0.74) [29].
Fraser et al. also studied men with intermediate-risk dis-
ease having radical therapy and demonstrated the utility
of a panel of 40 recurrent genomic alterations in identi-
fying those at highest risk of treatment failure [30].
Hence in the future, improved outcome discrimination
within the CPG sub-groups might be gained by includ-
ing such factors to add granularity. Men in CPG5 in par-
ticular clearly need a more aggressive and new approach
to treatment and may be the ideal cohort for molecular
sub-typing and targeted neo-adjuvant drugs combined
with radical therapy when planning new clinical trials
[31]. Conversely, it is likely to be a waste of resources to
do such profiling in men with already good outcomes
(e.g. those in CPG1). The CPG model may also be used
to construct tailored follow-up protocols. For instance,
men with CPG5 disease are likely to benefit most from
early adjuvant treatment after radical therapy compared
to men with CPG4 because of a much higher risk of a
poor outcome. Conversely, in a surveillance programme,
men in CPG1 are likely to only need a low-intensity
follow-up schedule. A trigger for conversion to treat-
ment might then be an increment to a higher CPG cat-
egory during follow-up evaluation.
Our study does have limitations. It has been built and
validated on men who have been diagnosed via trans-
rectal ultrasound-guided biopsy, which is known to
underestimate true histological grade and overall tumour
burden [32]. However, the contribution that more inten-
sive biopsy schema might make is currently uncertain.
The ProtecT Study, for instance, showed extremely low
mortality rates at 10 years in the surveillance cohort,
despite the fact that men only had this kind of biopsy
and at least a third likely harboured missed higher risk
disease [33]. We did not have data on biopsy core
involvement in our cohorts, and it was not a require-
ment for our model; thus, we cannot say if such granu-
larity would improve its prognostic power. We note that
biopsy core involvement is not included in contempor-
ary guidelines outside the USA, and there is no inter-
national consensus on its use [10–12]. We also did not
Table 4 Concordance indices of the current three-strata risk
group model (NICE) and Cambridge Prognostic Group (CPG)
from competing risk analysis in predicting prostate cancer-specific
mortality (p < 0.001 for both comparisons)
Concordance index (confidence interval)
Cohort (n) NICE CPG
PCBaSe (72,337) 0.77 (0.76–0.77) 0.81 (0.81–0.82)
Singapore (2550) 0.76 (0.73–0.80) 0.79 (0.76–0.83)
Table 5 Concordance indices of the current three-strata risk group model (NICE) and Cambridge Prognostic Group (CPG) from competing
risk analysis in predicting prostate cancer-specific mortality stratified by each treatment group (p < 0.0001 for all comparisons)
Cohort (n) Concordance index (confidence interval)
NICE CPG
Prostatectomy (20,586) 0.74 (0.72–0.77) 0.77 (0.74–0.79)
Radiotherapy (11,872) 0.69 (0.67–0.70) 0.73 (0.71–0.75)
Conservative management (11,757) 0.73 (0.71–0.74) 0.74 (0.73–0.76)
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sub-classify within T stages, but we have previously
noted the inaccuracies in its standard clinical use [34].
Our cohort predates the use of magnetic resonance im-
aging (MRI) for guided biopsies, which is already chan-
ging clinical practice [35, 36]. The CPG model, however,
will retain utility regardless of the biopsy approach, as it
is based on standard clinico-pathological variables.
Indeed, we have already demonstrated the use of the
model with MRI-based staging in predicting bone
metastasis at diagnosis [37]. About 11% of the PCBaSe
cohort had to be excluded, as we did not have all the
clinico-pathological details. Details of how missing data
is handled in PCBaSe have been previously reported
[38]. Finally, although we have included competing
mortality risks, our model does not include co-morbidity
as a variable. Indeed, none of the current UK and
European prostate cancer guidelines do so [10–12]. The
US National Comprehensive Cancer Network (NCCN)
guidelines also only go as far as to distinguish a life
expectancy of less or more than 5 years [39]. The CPG
model can of course be used alongside other tools to
predict other-cause mortality [40].
Conclusions
In summary, here we have confirmed the superiority of a
five-tiered prognostic system over the prevailing three-
tiered model in better stratifying prognosis in men with
non-metastatic prostate cancer. Our model is unique in that
it has been built from primary diagnostic source data linked
to PCM outcomes, it has been tested across different treat-
ment types and now has been validated in very large co-
horts of men. It is notable that in the USA the NCCN and
new AUA/ASTRO/SUO localised prostate cancer guide-
lines are both also endorsing five-strata systems for non-
metastatic disease although with different sub-categories
[25, 38]. While the AUA/ASTRO/SUO endorse splitting
the old intermediate-risk category, they do not recommend
a very high-risk sub-category. The NCCN criteria, in con-
trast, endorse a very high-risk category but do not endorse
splitting the intermediate-risk group. The CPG model un-
derscores the clinical relevance of sub-stratification of the
old intermediate-risk group in the new AUA/ASTRO/SUO
guidelines as well as the designation of a very high-risk cat-
egory but combines these two new sub-groups in the only
single, easy-to-reference, evidence-based model. While the
prognostic performance of the CPG model has remained
consistent in three cohorts from different countries, future
independent validation would strengthen its clinical util-
ity. Our model, however, can be used by any clinician any-
where in the world without requiring any additional data
or costs. Future work will determine how additional vari-
ables, including biopsy data and molecular profiles, can be
added to further individualise prognostic prediction both
across and within treatment sub-types.
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